| Product Code: ETC9936951 | Publication Date: Sep 2024 | Updated Date: Aug 2025 | Product Type: Market Research Report | |
| Publisher: 6Wresearch | Author: Sumit Sagar | No. of Pages: 75 | No. of Figures: 35 | No. of Tables: 20 |
1 Executive Summary |
2 Introduction |
2.1 Key Highlights of the Report |
2.2 Report Description |
2.3 Market Scope & Segmentation |
2.4 Research Methodology |
2.5 Assumptions |
3 United Kingdom (UK) Acute Myeloid Testing Market Overview |
3.1 United Kingdom (UK) Country Macro Economic Indicators |
3.2 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume, 2021 & 2031F |
3.3 United Kingdom (UK) Acute Myeloid Testing Market - Industry Life Cycle |
3.4 United Kingdom (UK) Acute Myeloid Testing Market - Porter's Five Forces |
3.5 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume Share, By Biomarker Type, 2021 & 2031F |
3.6 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume Share, By Product and Service, 2021 & 2031F |
3.7 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume Share, By Technology, 2021 & 2031F |
3.8 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume Share, By End User, 2021 & 2031F |
4 United Kingdom (UK) Acute Myeloid Testing Market Dynamics |
4.1 Impact Analysis |
4.2 Market Drivers |
4.2.1 Increasing prevalence of acute myeloid leukemia in the UK |
4.2.2 Advancements in diagnostic technologies for acute myeloid testing |
4.2.3 Growing awareness about the importance of early detection and treatment of acute myeloid leukemia |
4.3 Market Restraints |
4.3.1 Stringent regulatory requirements for diagnostic tests in the UK |
4.3.2 Limited access to specialized healthcare facilities in certain regions |
4.3.3 High cost associated with advanced testing procedures |
5 United Kingdom (UK) Acute Myeloid Testing Market Trends |
6 United Kingdom (UK) Acute Myeloid Testing Market, By Types |
6.1 United Kingdom (UK) Acute Myeloid Testing Market, By Biomarker Type |
6.1.1 Overview and Analysis |
6.1.2 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume, By Biomarker Type, 2021- 2031F |
6.1.3 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume, By Proteomic AML Biomarker, 2021- 2031F |
6.1.4 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume, By Genetic AML Biomarker, 2021- 2031F |
6.1.5 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume, By Epigenetic AML Biomarker, 2021- 2031F |
6.2 United Kingdom (UK) Acute Myeloid Testing Market, By Product and Service |
6.2.1 Overview and Analysis |
6.2.2 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume, By Services, 2021- 2031F |
6.2.3 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume, By Assay Kits, 2021- 2031F |
6.3 United Kingdom (UK) Acute Myeloid Testing Market, By Technology |
6.3.1 Overview and Analysis |
6.3.2 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume, By PCR, 2021- 2031F |
6.3.3 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume, By IHC, 2021- 2031F |
6.3.4 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume, By NGS, 2021- 2031F |
6.3.5 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume, By Cytogenetics, 2021- 2031F |
6.3.6 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume, By Others, 2021- 2031F |
6.4 United Kingdom (UK) Acute Myeloid Testing Market, By End User |
6.4.1 Overview and Analysis |
6.4.2 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume, By Clinical Laboratories, 2021- 2031F |
6.4.3 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume, By Hospitals, 2021- 2031F |
6.4.4 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume, By Academic and Research Institutes, 2021- 2031F |
6.4.5 United Kingdom (UK) Acute Myeloid Testing Market Revenues & Volume, By Cancer Diagnostic Institutes, 2021- 2031F |
7 United Kingdom (UK) Acute Myeloid Testing Market Import-Export Trade Statistics |
7.1 United Kingdom (UK) Acute Myeloid Testing Market Export to Major Countries |
7.2 United Kingdom (UK) Acute Myeloid Testing Market Imports from Major Countries |
8 United Kingdom (UK) Acute Myeloid Testing Market Key Performance Indicators |
8.1 Adoption rate of novel acute myeloid testing technologies in the UK |
8.2 Rate of diagnostic accuracy and efficiency in acute myeloid testing |
8.3 Number of research and development collaborations for improving acute myeloid testing methodologies |
9 United Kingdom (UK) Acute Myeloid Testing Market - Opportunity Assessment |
9.1 United Kingdom (UK) Acute Myeloid Testing Market Opportunity Assessment, By Biomarker Type, 2021 & 2031F |
9.2 United Kingdom (UK) Acute Myeloid Testing Market Opportunity Assessment, By Product and Service, 2021 & 2031F |
9.3 United Kingdom (UK) Acute Myeloid Testing Market Opportunity Assessment, By Technology, 2021 & 2031F |
9.4 United Kingdom (UK) Acute Myeloid Testing Market Opportunity Assessment, By End User, 2021 & 2031F |
10 United Kingdom (UK) Acute Myeloid Testing Market - Competitive Landscape |
10.1 United Kingdom (UK) Acute Myeloid Testing Market Revenue Share, By Companies, 2024 |
10.2 United Kingdom (UK) Acute Myeloid Testing Market Competitive Benchmarking, By Operating and Technical Parameters |
11 Company Profiles |
12 Recommendations |
13 Disclaimer |
Export potential enables firms to identify high-growth global markets with greater confidence by combining advanced trade intelligence with a structured quantitative methodology. The framework analyzes emerging demand trends and country-level import patterns while integrating macroeconomic and trade datasets such as GDP and population forecasts, bilateral import–export flows, tariff structures, elasticity differentials between developed and developing economies, geographic distance, and import demand projections. Using weighted trade values from 2020–2024 as the base period to project country-to-country export potential for 2030, these inputs are operationalized through calculated drivers such as gravity model parameters, tariff impact factors, and projected GDP per-capita growth. Through an analysis of hidden potentials, demand hotspots, and market conditions that are most favorable to success, this method enables firms to focus on target countries, maximize returns, and global expansion with data, backed by accuracy.
By factoring in the projected importer demand gap that is currently unmet and could be potential opportunity, it identifies the potential for the Exporter (Country) among 190 countries, against the general trade analysis, which identifies the biggest importer or exporter.
To discover high-growth global markets and optimize your business strategy:
Click Here